Patent-Protected Medical Device

Vascular Access, Reimagined

The first multidirectional vascular access system. A single needle stick enables treatment in any direction of the vessel, reducing complications, eliminating redundant procedures, and improving patient outcomes.

Access Point Antegrade Retrograde Distal Proximal Single Access Point  •  Multidirectional Treatment

Current vascular access is unidirectional. Vascular disease is not.

Standard endovascular sheaths only allow devices to travel in one direction from the access point. When disease affects multiple vessels or the contralateral limb, clinicians face a difficult choice:

A second procedure — requiring the patient to return, increasing risk and cost.

A second access point — doubling the complication rate from the #1 source of endovascular complications.

Complex workarounds — requiring multiple hands, radiation exposure, and increased procedure time.

5-8%
Access complication rate across all endovascular procedures
#1
Complication source in endovascular surgery
2x
Procedures often required for bilateral disease
3+
Hands needed for current crossover techniques

One Access Point. Every Direction.

The Upstream Access system is a multidirectional vascular access device that enables treatment in any direction from a single needle stick.

Multidirectional Access

Treat vessels in any direction from a single femoral access site. No second puncture, no second procedure.

Balloon Anchor

An atraumatic balloon anchor secures the sheath within the vessel, preventing accidental loss of access during the procedure.

Fewer Complications

By eliminating the need for a second access point, the system reduces the #1 complication source in endovascular procedures.

Familiar Components

Built on technology clinicians already know — standard sheaths, guidewires, and catheters — minimizing the learning curve.

Broad Applicability

Applicable across PAD, DVT, dialysis access, and other endovascular specialties including cardiology and interventional radiology.

FDA Pathway Clear

Pre-submission or direct-to-510(k) pathway. FDA likely will not require patient testing.

Validated and Funded

$134K+
Innovation grant funding received
2
Patent applications filed (US & PCT)
NSF
I-Corps customer discovery completed
Proven
Animal proof of concept completed

Interested in Learning More?

We're seeking strategic partners, licensees, and investors to bring multidirectional vascular access to patients worldwide.

Request Pitch Deck